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Abstract
Background: Adeno-associated virus-2 (AAV-2)-mediated gene therapy is quite suitable for local or regional
application in head and neck cancer squamous cell carcinoma (HNSCC). However, its low transduction efficiency
has limited its further development as a therapeutic agent. DNA damaging agents have been shown to enhance
AAV-mediated transgene expression. Cisplatin, one of the most effective chemotherapeutic agents, has been
recognized to cause cancer cell death by apoptosis with a severe toxicity. This study aims to evaluate the role of
cisplatin in AAV-mediated tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and the effect
on HNSCC both in vitro and in vivo.
Methods: Five human HNSCC cell lines were treated with recombinant soluble TRAIL (rsTRAIL) and infected with
AAV/TRAIL to estimate the sensitivity of the cancer cells to TRAIL-induced cytotoxicity. KB cells were infected with
AAV/EGFP with or without cisplatin pretreatment to evaluate the effect of cisplatin on AAV-mediated gene
expression. TRAIL expression was detected by ELISA and Western blot. Cytotoxicity was measured by MTT assay
and Western blot analysis for caspase-3 and -8 activations. Following the in vitro experiments, TRAIL expression and
its tumoricidal activity were analyzed in nude mice with subcutaneous xenografts of HNSCC.
Results: HNSCC cell lines showed different sensitivities to rsTRAIL, and KB cells possessed both highest
transduction efficacy of AAV and sensitivity to TRAIL among five cell lines. Preincubation of KB cells with
subtherapeutic dosage of cisplatin significantly augmented AAV-mediated transgene expression in a heparin sulfate
proteoglycan (HSPG)-dependent manner. Furthermore, cisplatin enhanced the killing efficacy of AAV/TRAIL by 3-
fold on KB cell line. The AAV mediated TRAIL expression was observed in the xenografted tumors and significantly
enhanced by cisplatin. AAV/TRAIL suppressed the tumors growth and cisplatin augmented the tumoricidal activity
by two-fold. Furthermore, Combination treatment reduced cisplatin-caused body weight loss in nude mice.
Conclusion: The combination of AAV-mediated TRAIL gene expression and cisplatin had synergistic therapeutic
effects on head and neck cancers and reduced the potential toxicity of cisplatin. These findings suggest that the
combination of AAV/TRAIL and cisplatin may be a promising strategy for HNSCC therapy.
Background
Head and neck cancer actually includes many different
malignancies. The most common type of cancer in the
head and neck is squamous cell carcinoma (HNSCC),
originating from the mucosal epithelium of the nose,
mouth and throat [1]. Local control of HNSCC is
essential, and administering anticancer drugs directly
into various lesion sites by injection is comparatively
easy [2]. Therefore, adaptation of traditional chemother-
apeutics to local and regional administration techniques
in treating head and neck cancers is actively pursued to
provide higher local concentrations of otherwise sys-
temically toxic drugs. Cisplatin is one of most successful
chemotherapeutic drugs of choice for head and neck
cancers; however, it produces major toxicities to normal
cells and organs at the concentrations necessary for
effective treatment of malignancies [3,4]. A combination
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of cisplatin with other therapeutic method, such as gene
therapy, has become attractive treatment project [5,6].
Gene therapy is considered to have an enormous
potential benefit and involves various delivery vehicles
that can transfer therapeutic genes to tumor cells.
Adeno-associated virus (AAV) is a small virus which has
attracted considerable interest from gene therapy
researchers due to a number of features, such as lack of
pathogenicity, infection non-dividing cells and stably
integration into the host cell genome at a specific site in
the human chromosome. AAV also presents very low
immunogenicity, seemingly restricted to generation of
neutralizing antibodies. These features make AAV a
very attractive candidate for creating viral vectors for
gene therapy [7,8]. To date, AAV vectors have been
used for many clinical trials for treatment of some kinds
of tumors [9-11].
AAV vectors have a broad host range and can trans-
duce head and neck cancer cells [12]. However, an
obstacle to these applications is low transgene expres-
sion efficiency, mainly due to a limited second strand
synthesis [13,14]. Previous studies reported that DNA-
damaging agents, such as UV light, gamma irradiation,
cis-platinum, and tritiated thymidine can significantly
increase the efficiency of AAV transduction in various
cells, including nondividing cells [15], airway cells [16],
neuronal cells [17] and cancer cells [12,18,19]. Cisplatin
is an alkylating agent that targets DNA and results in
bulky adducts as well as intra- and inter-strand crosslink
[20,21]. Based on these promising characters, an
alternative therapeutic modality, combination therapy of
AAV-mediated gene expression and cisplatin might be a
feasible candidate for HNSCC therapy.
Now being investigated for the treatment of HNSCC
includes many gene transfer strategies that involve
introduction of genes that directly kill tumor cells,
restore of a defective tumor-suppressor gene, or trigger
tumor apoptosis. Tumor necrosis factor (TNF)-related
apoptosis-inducing ligand (TRAIL) is a potent apoptosis
inducer that limits tumor growth without damaging
normal cells and tissues in vivo and in vitro [22]. Mohr
et al. demonstrated that long-term expression of TRAIL
mediated by AAV led to a marked suppression of color-
ectal tumors in mouse with a single intratumoral injec-
tion of AAV/TRAIL vector [23]. We previously showed
that AAV-mediated TRAIL gene therapy significantly
suppressed the growth of human tumor cells trans-
planted in the liver [24,25] and lung [26] of mouse
models.
In the present study, we investigated the role of cispla-
tin in AAV-mediated TRAIL gene therapy and its cyto-
toxic effect on HNSCC. We demonstrated that
application of cisplatin significantly facilitated AAV/
TRAIL transfer and TRAIL-induced apoptosis in
HNSCC KB cell line in vitro and this combination sig-
nificantly suppressed tumor growth in nude mice inocu-
lated with KB subcutaneously. Furthermore, AAV/
TRAIL was found to protect tumor-bearing mice from
cisplatin-caused body weight loss. These findings sug-
gest that combination of cisplatin and AAV/TRAIL may
have synergistic therapeutic effects on the treatment of
HNSCC patients.
Methods
Cell culture and reagents
Five human HNSCC cell lines were used to estimate the
sensitivity to TRAIL. Human adenoid cystic carcinoma
cell line Acc-2, tongue squamous cell carcinoma TCA
and laryngeal carcinoma cell line Hep-2 were purchased
from the Cell Culture Centre of Institute of Basic Medi-
cal Sciences, Chinese Academy of Medical Sciences
(Beijing) and cultured in RPMI-1640 medium (Gibco
BRL, Grand Island, NY) with 10% fetal bovine serum
(FBS) (Hyclone, South American origin). Human oral
squamous carcinoma cell line KB and nasopharyngeal
carcinoma cell line CNE were purchased from China
Center for Type Culture Collection, Wuhan University,
and cultured in modified Eagle’s medium with 2 mM L-
glutamine and 0.1 mM non-essential amino-acids
(MEM-NEAA) (Cell Culture Centre of Institute of Basic
Medical Sciences, Chinese Academy of Medical
Sciences, Beijing), 1.0 mM sodium pyruvate, 100 U/mL
penicillin, 100 μg/mL streptomycin sulfate and 10% FBS.
All cell cultures were maintained at 37°C in a humidi-
fied atmosphere of 5% CO2. Immunophenotyping
heparin (10,000 U/mL; Changzhou Qianhong Bio-
pharma Co., Ltd., Changzhou) was used for blocking
infectious AAV experiments.
Construction of AAV/TRAIL and AAV/EGFP vectors
AAV/TRAIL and AAV/EGFP were constructed as pre-
viously described [24] with a little of modification. Briefly,
TRAIL95-281 cDNA with a woodchuck hepatitis B virus
post-transcriptional regulatory element (WPRE) was
amplified by PCR and then inserted into an AAV expres-
sion vector under control of CAG (cytomegalovirus
enhancer plus chicken b-actin) promoter. Recombinant
AAV vector encoding enhanced green fluorescent pro-
tein (AAV/EGFP) was constructed as control. Recombi-
nant AAV viral particles were generated and purified as
described [24].
Cell infection with AAV/TRAIL and treatment with
cisplatin
Adherent KB cells were removed from culture flasks and
seeded in the cell culture plates at a density of 1 × 104/mL.
After an overnight culture, the medium was removed and
replaced with the complete medium with the absence or
Jiang et al. BMC Cancer 2011, 11:54
http://www.biomedcentral.com/1471-2407/11/54
Page 2 of 11
presence of cisplatin (200 ng/mL) (Qilu pharmaceutical
Co., Ltd, Shandong). Two hours later, the cells were
infected with AAV/TRAIL and AAV/EGFP viruses at a
multiplicity of infection (MOI) of 1 × 105 infectious parti-
cles per cell in FBS free and antibiotics free medium in the
absence or presence of cisplatin. Four hours later, the med-
ium was replaced with the complete medium in the
absence or presence of cisplatin, and the cells went on
being incubated for 72 h.
To assess the gene transduction in the presence of
soluble heparin sulfate, a competitive inhibitor of the
interaction between AAV and its primary attachment
receptor, the cell surface molecule heparin sulfate pro-
teoglycan (HSPG) was used to determine whether the
robust gene transfer seen in KB cells was in fact due to
their residual HSPG expression or other cell surface
molecules. AAV/EGFP was incubated with 500 IU solu-
ble heparin sulfate for 2 h at 37°C, and then the mixture
was subjected to KB cells as control.
Cell viability assay
Cell viability was quantified by a short-term microcul-
ture tetrazolium (MTT) assay. In a 96-well microplate,
1 × 104 cells per well were exposed to the treatments
with recombinant soluble TRAIL (rsTRAIL) (Xingpeng
Biotech Co., Shenzhen) for 24 h, cisplatin alone, AAV/
TRAIL alone or the combination of both for 72 h,
respectively. The media were replaced with 90 μL of
free-serum medium and 10 μL of MTT solution (5 mg/
mL in sterile phosphate-buffered saline). After 4-hour
incubation at 37°C, the MTT solution in the wells was
replaced with 100 μL dimethyl sulfoxide (DMSO). The
absorption at 570 nm (OD570) was measured on a spec-
trophotometer. The cell viability was converted and
expressed as the percentage of the control. Results were
expressed as the mean OD for selected paradigms per-
formed in duplicate (n = 3). The cells without any treat-
ment were used as negative control.
ELISA
The TRAIL concentrations in culture medium of KB
cells with various treatments were measured by using a
Quantikine human TRAIL/TNFSF10 immunoassay kit
(R&D Systems; Minneapolis, MN) according to the
manufacturer’s instructions. The absorbance at 490 nm
(OD490) was measured on a microplate reader.
Western blot assay
To detect caspase activation in TRAIL-induced apopto-
sis, KB cells was pretreated with pan-caspase inhibitor
Z-VAD-fmk followed by treatment with cisplatin and/or
AAV/TRAIL. The cells were lysed for 30 min at 4°C in
PBS with 1% NP-40 and protease inhibitor cocktail
tablet (Roche, Mannheim) followed by high-speed
centrifugation. Protein concentration was assayed by
using bicinchoninic acid (Pierce, Rockford, IL). Total
proteins were separated on a 10% SDS-PAGE. Immuno-
detection of TRAIL, caspase 8, caspase 3 and GAPDH
was carried out by using rabbit anti-TRAIL antibody
(Santa Cruz Biotechnology, Santa Cruz, CA), mouse
anti-caspase 8 and rabbit anti-caspase 3 (Cell Signaling
Technology, Danvers, MA) at 4°C overnight. The pro-
teins in the gel were transferred onto a polyvinylidene
difluoride (PVDF) membrane, and the membrane was
incubated at 4°C for 16 h with the primary antibody.
After three washes with TBST, the membrane was incu-
bated with biotinylated goat anti-mouse IgG or goat
anti-rabbit IgG for 1 h at room temperature. After thor-
oughly washing with TBST, the specific protein was
visualized with enhanced luminescence reagents (Hyper-
film ECL, Amersham Biosciences, Buckinghamshire) fol-
lowed by exposure to X-ray film for 3 min. Equal
amount of protein loading was controlled by GAPDH in
the sample and visualized with mouse anti-GAPDH
mAb (Zhongshan Goldenbridge Biotechnology Co. Ltd,
Beijing).
Immunochemistry assay
Cryosections (10 μm thickness) prepared from tumors
were incubated with the specific primary anti-TRAIL
antibody (Santa Cruz Biotechnology, Santa Cruz, CA)
overnight, washed, subsequently incubated for 30 min
with appropriate HRP-conjugated goat anti-rabbit IgG
secondary antibody (Santa Cruz Biotechnology, Santa
Cruz, CA) in blocking buffer and DAB (Vector Labora-
tories, Burlingame, CA) as a substrate for the visualiza-
tion of antigen-antibody complex.
KB metastatic models and assessment of tumor growth in
vivo
Four to six week’s old male BALB/c nude mice with
average weight of about 18 g were provided by the Insti-
tute of Zoological Sciences, Chinese Academy of Medi-
cal Sciences, Beijing. KB cells were infected in vitro for
four hours with AAV/TRAIL or AAV/null at 1 × 104
v.g./cell, and the AAV/TRAIL or AAV/null infected
cells (1.5 × 106) were inoculated into the right dorsal
flanks of the mice (n = 6). The tumor volume was mea-
sured with calipers twice weekly for length and width,
and then calculated by the formula of [(length ×
width2)/2]. TRAIL expression in tumor tissues was
checked by ELISA.
To evaluate the anti-tumor effect of AAV/TRAIL in
vivo, 1.5 × 106 KB cells were injected subcutaneously at
right back of nude mice. When the tumor volumes
reached approximately 60 mm3 on the seventh day post-
injection, the animals were divided into four groups (n =
6) and two groups of animals were given AAV/TRAIL
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(1 × 1010 v.g./100 μL) intratumorally or cisplatin (6 mg/
kg) intraperitoneally (i. p.), respectively. One group of
the animals was treated with 6 mg/kg cisplatin plus 1 ×
1010 v.g of AAV/TRAIL simultaneously. The control
group of the animals was injected with AAV/null intra-
tumorally and PBS i.p. injected. The tumor volume was
measured and calculated. The animals were euthanized
on the 33th day post-treatment, and the tumors were
processed for histology analysis. Mouse sera were col-
lected for kidney function analysis of blood urea nitro-
gen (BUN) and creatinine (Cr) using an AU2700
Automatic Biochemical Analyzer (Olympus Co., Ltd.).
All animal experiments were approved by the Commit-
tee of Use and Care of Animals, Chinese Academy of
Medical Sciences.
Statistical analysis
Data are presented as mean ± SD. Statistical analysis
was conducted using the software package Minitab
(version 15.1.0.0; Minitab, State College, PA). Signifi-
cance was assessed by Student’s t test and one-way
ANOVA followed by Bonferroni t test for the com-
parisons of multiple means, or by Kruskal-Wallis test
and subsequent pair-wise comparisons. The p value
was considered to be statistically significant when less
than 0.05.
Results
Human head and neck cancer cell lines possess different
sensitivities to rsTRAIL
We first examined the sensitivity of HNSCC cell lines to
rsTRAIL. As shown in Figure 1A, treatment with var-
ious concentrations of rsTRAIL for 24 h caused various
viability reductions in five head and neck cell lines.
Apoptosis in TCA, Hep-2 and CNE cells was about
17-30% at the concentration of 1.0 μg/mL rsTRAIL, sug-
gesting these cells are resistant to rsTRAIL killing. Acc-
2 was about 40% apoptosis under the treatment of
rsTRAIL (1.0 μg/mL), showing a mild sensitivity to
rsTRAIL. The viability of KB cells were 40% and 70%,
respectively, in the presence of rsTRAIL of 0.5 and 1.0
μg/mL, indicating that KB is the highest susceptible to
rsTRAIL cytotoxicity among the five HNSCC cell lines.
To further assess the sensitivity of cell lines to AAV-
mediated TRAIL cytotoxicity the five cell lines were
infected by AAV/TRAIL particles for 72 hours, respec-
tively. As shown in Figure 1B, the viability of TCA,
Hep-2 and CNE cells were about 90%, while KB cells
70%, suggesting that KB cells are both relatively high
transduction efficacy of AAV and high sensitivity to
AAV-mediated TRAIL cytotoxicity. Accordingly, we
used KB as human HNSCC model to determine the effi-
cacy of combination of AAV/TRAIL and cisplatin.
Cisplatin enhances AAV-mediated EGFP expression in KB
cells in a HSPG-dependent manner
To evaluate the effect of cisplatin on AAV-mediated
gene expression, KB cells infected with AAV/EGFP par-
ticles were treated with cisplatin. The inhibitory rate of
cisplatin alone was first tested to determine a sub-toxic
dosage that induces minimal cell death (less than 25%).
As indicated in Figure 2A, cisplatin induced cell death
in a dose-dependent manner during 72 hour’s treatment
in KB cells. When the cells were treated with cisplatin
of 200 ng/mL for 72 hours, the viability of KB dropped
to 80% of untreated cells, indicating that 200 ng/mL of
cisplatin is the sub-toxic dosage and then adapted for
the combination with AAV/TRAIL.
Then, AAV transduction in response to cisplatin treat-
ment was evaluated using the viral AAV/EGFP. KB cells
Figure 1 Effects of rsTRAIL and AAV/TRAIL on cell viability in HNSCC cell lines. (A) Treatment with rsTRAIL (50-1000 ng/mL) for 24 h;
(B) transfected with AAV/TRAIL (MOI = 1 × 105 v.g.) for 72 h. Values are mean of three independent experiments with error bar representing
standard deviation of the mean.
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were pre-incubated with cisplatin for 2 h followed by
infection with AAV/EGFP. As shown in Figure 2B(a-c),
EGFP expression was markedly increased compared to
either without cisplatin or with cisplatin treatment post
AAV/EGFP transduction, suggesting that cisplatin could
enhance infection of AAV in KB cells. To determine
whether cisplatin was capable of inducing AAV transduc-
tion in various HNSCC cell lines, four cell lines except
KB were infected with AAV/EGFP and/or cisplatin. The
results showed that these cisplatin-treated HNSCC cells
all became susceptible to AAV/EGFP infection in com-
parison with untreated control (data not shown).
To explore whether cisplatin could enhance AAV-
binding to its primary attachment receptor HSPG, 1 ×
105 v.g. of AAV/EGFP were mixed with 500 IU heparin,
an endogenesis inhibitor of AAV infection, and incu-
bated with KB cells for 48 h. As shown in Figure 2Bd
and 2Be, transduction of KB cells was completely
blocked by heparin, no matter in the presence or
absence of cisplatin, suggesting that cisplatin-induced
AAV-mediated EGFP expression in KB cells was in a
HSPG-dependent manner and not involved in additional
cell surface molecules mediating attachment and entry
of AAV.
Cisplatin pre-treatment increases AAV/TRAIL-induced
apoptosis in KB cells
To evaluate the potential effect of the combination of
AAV/TRAIL and cisplatin on HNSCC cells, TRAIL
expression and its cytotoxicity were determined. As
shown in Figure 3A, TRAIL expression in KB cells trea-
ted with cisplatin (200 ng/mL) for 2 h followed by
AAV/TRAIL infection was increased 2.3-fold over AAV/
TRAIL alone, and 1.75-fold over AAV/TRAIL transduc-
tion first and followed by cisplatin. Effects of treatment
with the combination on TRAIL expression in KB cells
were assessed by Western blot analysis. The combina-
tion of AAV/TRAIL and cisplatin significantly increased
TRAIL expression compared to either treatment (Figure
3B). Pre-treatment with cisplatin and followed by AAV/
TRAIL in KB cells caused 57.6% inhibition of the cell
viability, which was much higher than either cisplatin
(11%) or AAV/TRAIL (20%) only, or AAV/TRAIL trans-
duction first and followed by cisplatin (28%) (Figure 3C),
indicating that there is a synergetic effect of the combi-
nation treatment on the viability of KB cells. To confirm
the cell death property, the activated forms of caspase-3
and caspase-8 were measured by Western blot analysis.
As shown in Figure 3D, the intensities of cleaved cas-
pase-3 and -8 bands were almost similar in KB cells
treated with AAV/TRAIL or cisplatin alone. Treatment
with cisplatin and AAV/TRAIL resulted in a significant
increase in the activation of caspase-3 and -8 over either
of them alone. Additionally, pre-incubation of KB with
the caspase inhibitor z-VAD-fmk completely prevented
cleavage of caspase-3 and -8. These results suggest that
cisplatin pre-treatment increases AAV/TRAIL-induced
apoptosis profoundly in KB cells.
Figure 2 Cisplatin exhibits dose-dependent cytotoxicity and augments AAV/EGFP transduction in KB cell line. (A) Treatment with
cisplatin (50-5000 ng/mL) for 72 h. (B) Fluorescence microscopy of KB cells without (a) or with treatment of cisplatin for 2 h before (b) and after
(c) AAV/EGFP infection. For the competition experiments, KB cells were infected with the virus and incubated for 2 h at 37°C in the presence of
500 IU heparin sulfate (d and e). Values are mean of three independent experiments with error bar representing standard deviation of the mean.
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Combination of AAV/TRAIL and cisplatin suppresses the
growth of HNSCC xenografts in nude mice
We further investigated the effect of the combination of
AAV/TRAIL and cisplatin on tumor formation and
growth in nude mice transplanted with KB cells. KB cells
infected with AAV/TRAIL or AAV/null were subcuta-
neously inoculated into the right dorsal flanks of nude
mice and tumor formation was monitored twice weekly
during a period of 33 day’s experiment. Notably, the
mean volume of the tumors generated from the KB cells
infected with AAV/TRAIL was about 45% of that gener-
ated from the cells infected with AAV/null (Figure 4).
ELISA analysis revealed that TRAIL expression in the
tumors infected with AAV/TRAIL on the 21st day was
about 70 ng/mg tissue, but not in the tumors infected
with AAV/null, suggesting that AAV-mediated TRAIL
expression effectively suppresses tumor formation in the
animal model.
We next attempted to find out whether cisplatin pre-
treatment followed by AAV/TRAIL infection was
Figure 3 Cisplatin enhances AAV-mediated TRAIL expression and apoptosis in KB cells. KB cells pre-treated or post-treated with cisplatin
were transducted with AAV/TRAIL for 72 h, the cells were harvested and TRAIL expression was analyzed by (A) ELISA assay and (B) Western blot
assay. Purified rsTRAIL was used as a standard. The cells pre-treated with cisplatin (200 ng/mL for 2 h) and apoptosis was detected by MTT assay
(C) and (D) Western blot analysis for the activation of caspase-8 and -3 in KB cells. Densitometric analysis showing change in optical density of
TRAIL, cleaved caspase-3 and -8 bands. GAPDH expression was used as adjustment. Values are mean of three independent experiments with
error bar representing standard deviation of the mean. **P < 0.01 compared to the values obtained with the equivalent dose of AAV/TRAIL
alone. ##P < 0.01 compared to the sum effect of AAV/TRAIL and cisplatin.
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effectively blocked the tumor growth in an established
HNSCC mouse model. KB cells were subcutaneously
injected into the right thighs of nude mice. When reach-
ing an average tumor volume of about 60 mm3, the
mice were randomly divided into 4 groups (n = 6) admi-
nistrated with PBS plus AAV/null as control, AAV/
TRAIL, cisplatin, and the combination of AAV/TRAIL
plus cisplatin, respectively. On the 14th day of post-
treatment, the tumors in the mice treated with the com-
bination of AAV/TRAIL and cisplatin began to grow
slower than the other three groups. On the 33rd day of
post-treatment, the tumor size in the combination
group was inhibited by 65%, to a much greater extent
than that of mice treated with the intratumor injection
of AAV/TRAIL only (36%) or single intraperitoneal
administration with cisplatin (21%) (Figure 5A). The
tumor weights in the combination group were signifi-
cantly lower than that treated with either of them (P <
0.05) and AAV/null group (P < 0.01) (Figure 5B). Histo-
logical analysis showed a substantial number of TRAIL
positive cells in the tumor tissue infected with AAV/
TRAIL alone and combination of AAV/TRAIL plus cis-
platin, but few in the tumor tissue infected with AAV/
null (Figure 5C). These data indicate that combination
of AAV/TRAIL and cisplatin suppresses human tumor
formation and growth significantly in nude mice.
AAV/TRAIL reduces cisplatin-caused body weight loss in
nude mice
Interestingly, we observed that the animals received cis-
platin 6 mg/kg, i.p. showed a decrease in their body
weight by 2.2 ± 0.8 g compared to AAV/null and AAV/
TRAIL treated animals, which gained 1.8 ± 0.5 g body
weight (P < 0.01) during the period of 33 day’s experi-
ment, and the animal body weight in the combination
group was almost no change (Figure 6A). To eliminate
the effect of tumor weight on the body weight, net body
weight of the mice, namely the tumor weight subtracted
from the whole body weight, was calculated. As shown
in Figure 6B, the net body weight in the cisplatin group
was the lowest among the three groups and there
was statistically significant difference compared with
AAV/null group (P < 0.01) and the combination group
(P < 0.05).
Discussion
Goals of cancer treatment generally consist of removal
of cancer load, maintenance of quality of life, and pre-
vention of subsequent primary tumors. Despite
improved chemotherapeutic strategies, resistance and
toxic side effects of many tumors such as head and neck
cancers to current treatment protocols remain major
concerns in tumor therapy. Therefore, more effective
therapeutic modalities, being selective for tumor cells
without toxicity for normal cells, are preferred. Head
and neck cancers are accessible to intratumoral injection
therapy and good candidates for trials of gene therapy.
The recombinant vectors based on AAV, a non-patho-
genic virus with a single-stranded DNA genome, have a
broad host range and can transduce head and neck
cancer cells, so that they are currently being used in a
number of clinical trials and may become an important
component for the therapy of tumor patients [9-11].
However, a major challenge of AAV-mediated gene
therapy is to improve its transduction and expression
efficiency in targeted tissues. In the present study, we
report that chemotherapeutic drug cisplatin enhanced
AAV vector-mediated TRAIL expression and cytocidal
effect on HNSCC cells. This finding was confirmed in
animal model with xenografts of HNSCC that cisplatin
enhanced AAV-mediated TRAIL expression and aug-
mented the antitumor activity of AAV/TRAIL, suggest-
ing that combination of AAV/TRAIL and cisplatin is
significantly effective in the treatment of HNSCC and
may lead to reduction of the cisplatin toxicity. It is rea-
sonable to expect the use of AAV/TRAIL for local or
regional delivery to bulky cancers in conjunction with
systemic cisplatin-based chemotherapy for optimal and
synergistic antitumor effect.
As a chemotherapeutic agent, cisplatin is preciously
reported to significantly enhance AAV transduction in
some kinds of cells. However, whether cisplatin is able
to induce AAV transduction in squamous cell carci-
noma cells has never been tested. In the present study,
we evaluated the AAV transduction in response to cis-
platin treatment using AAV/EGFP viral particles. Pre-
treating KB cells with subtherapeutic dosage of cisplatin
before AAV infection resulted in a significant enhance-
ment of transgene expression of both AAV/EGFP and
AAV/TRAIL. However, the underlying molecular
Figure 4 Infection of AAV/TRAIL suppresses tumor formation
and growth in BALB/c nude mice. KB cells were infected with
AAV/TRAIL or AAV/null for 4 h in vitro, and then injected into nude
mice subcutaneously. The tumor formation was observed for 33
days. Values are mean with error bar representing standard
deviation of the mean (n = 6).
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mechanism of this phenomenon has not been clearly
elucidated. Membrane-associated HSPG, a principal
attachment receptor for AAV mediating both attach-
ment and infection of target cells, has been reported
[27]. It is not known whether the increased AAV trans-
duction when combined with cisplatin would be
mediated by similar receptor. We conducted further
experiments to address this possibility. Inhibition of
Figure 5 Synergistic antitumor effect of the combination of AAV/TRAIL and cisplatin in vivo. (A) KB cells were inoculated into the right
thighs of BALB/c nude mice. When the tumor size was reached to 60 mm3, the mice were received an intratumoral injection of AAV/TRAIL,
intraperitoneal injection of cisplatin and the combination treatment. The tumor volume was measured and calculated. The animals were
euthanized on the day 33 post-treatment. The tumor weights were determined (B) and processed for immunohistochemistry analysis (× 200) (C).
Values are mean with error bar representing standard deviation of the mean (n = 6).
*P < 0.05, **P < 0.01 compared to AAV/null.
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AAV attachment and infection was shown to be
achieved in competition experiment using heparin sul-
fate, a molecule chemically very similar to HSPGs thus
functioning as a soluble receptor analog. Transgene
expression was significantly blocked by pre-incubation
of the cells with heparin sulfate in KB cells in the pre-
sence or absence of cisplatin, suggesting that cisplatin-
induced AAV permissiveness in KB cells is a normal
HSPG-dependent cell entry pathway. For the potential
mechanism of the synergistic effect on AAV transduc-
tion, previous studies reported that cells exposed to
DNA-damaging agents might provide the sites for AAV
integration or lead to induction of repair enzymes and
factors modulating cell cycle progression [15]. The
machinery of cellular DNA repair synthesis may play an
important role in converting the single-stranded AAV
vector genome to a double-stranded form, which is acti-
vated by cisplatin [13,28]. Platinum-based cisplatin is
the first member of a class of anti-cancer drugs which
react in vivo, binding to and causing cross-linking of
DNA which ultimately triggers apoptosis. Thus, it is
possible that the cisplatin-induced AAV permissiveness
is contributed in part by overcoming barriers for the
second strand DNA synthesis. Increased transduction
appears to reflect an increase in the number of input
vector genomes converted to a form that allows gene
expression [15].
As predicted, combination of AAV-mediated TRAIL
expression and cisplatin enhanced the cytotoxicity and
apoptosis efficacy in KB cancer cells. However, it was
not clear whether there were other factors except
increased TRAIL protein likely responsible for the
enhancement of cisplatin-induced apoptosis. In previous
studies, it was shown that the cytotoxicity efficacy of
TRAIL was enhanced by cisplatin [29-34]. Furthermore,
AAV infection alone was not sufficient to trigger apop-
tosis, but that in combination with cisplatin, it could
enhance cell death in HeLa and A549 cells [35]. In the
present study, we failed to demonstrate a synergistic
cytotoxic effect neither the post-treatment of cisplatin
after AAV/TRAIL infection (Figure 3C) nor the combi-
nation of rsTRAIL and various dosages of cisplatin in
KB cells (Additional file 1 Figure S1). So the main
mechanism underlying of the cisplatin-mediated
enhancement of AAV cytotoxic efficacy might be only
involved in cisplatin-induced AAV-mediated TRAIL
expression in KB cells.
The synergistic tumoricidal activity of AAV-mediated
TRAIL and cisplatin in KB cells prompted us to evalu-
ate the therapeutic efficacy in animal models. It was
observed that TRAIL protein expression at high level
effectively suppressed both tumor formation and growth
in nude mice transplanted with KB cells pre-infected
with AAV/TRAIL in vitro. Moreover, in the other
tumor model of intratumor delivery of AAV/TRAIL,
our data demonstrated that the combination of AAV/
TRAIL gene therapy and chemotherapeutic agent cispla-
tin suppressed tumor growth more efficiently than
either alone, suggesting that the cytotoxicity mediated
by AAV/TRAIL can be strengthened by cisplatin. How-
ever, we failed to detect TRAIL protein in tumor tissues
by immunoblotting or ELISA using anti-TRAIL anti-
body in this model. Nevertheless, we observed signifi-
cant inhibition of tumor growth (Figure 5A and 5B),
suggesting that the biologically active TRAIL was
expressed even at very low level in tumors. Yoo J et al.
[36] also could not detect secreted TRAIL (sTRAIL)
protein in mice sera after intravenous delivery of rAAV-
sTRAIL via the tail vein, but they did observe a number
of apoptotic tumor cells and significant inhibition of
tumor growth, suggesting that TRAIL could be secreted
into the body circulation and inhibit tumor formation
at a distant site even at undetectable expression level. In
our study, the secreted form of TRAIL was perhaps dis-
tributed inhomogeneously in relative big tumor tissues
(about 2.5 grams) so that it was difficult for us to mea-
sure TRAIL protein in a little random cut tissues (100
mg or so). However, we successfully detected TRAIL
expression in tumor tissues by immunochemistry assay
Figure 6 The changes of body weight (A) and net body weight
(the tumor weight subtracted from the total body weight) (B)
of the mice in the respective treatment groups. Values are mean
with error bar representing standard deviation of the mean (n = 6).
**P < 0.01 compared to AAV/null, #P < 0.05 compared to the
combination group.
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and scanning of the whole tumor sections. In addition,
it was interestingly to note that in the experiments
using rsTRAIL a minimum of 100-200 ng/mL was
needed to evaluate the apoptosis effects (Figure 1A and
2A), whereas AAV-mediated TRAIL expression yielding
only 150 pg/mL reached similar cytotoxicity to HNSCC
cells (Figure 3A). This difference might be caused by
the different origins of TRAIL proteins, the former pro-
duced in bacteria (rsTRAIL) and the latter from AAV-
mediated gene expression in eukaryotic cells where
TRAIL could have its biological activity at very low
concentration.
Despite cisplatin as one of the most widely used and
most potent chemotherapy drugs, its side effects in nor-
mal tissues and organs limits its use and efficacy in can-
cer therapy. In the present study, intraperitoneal
administration of cisplatin resulted in significant reduc-
tion of body weight. AAV/TRAIL was found to protect
tumor-bearing mice from cisplatin-caused body weight
loss. To further assess AAV/TRAIL protection from cis-
platin toxicity, we administrated AAV/TRAIL systemi-
cally in normal nude mice without tumors. As a result,
the body weights in the combination of AAV/TRAIL
plus cisplatin group were significantly higher than the
mice treated with single cisplatin (Figure 6), suggesting
that the soluble TRAIL secreted into body circulation
might attenuate cisplatin-caused systemic toxicity. We
also detected the nephrotoxicity of cisplatin in nude
mice assessed by blood urea BUN and Cr levels. While
BUN and Cr levels were no significant changes among
the experimental animals on the 33rd day after cisplatin
treatment (data not shown). The reason might be that
low dose of cisplatin causes low nephrotoxicity and
early recovery from the impaired renal function.
Whether AAV/TRAIL protects against cisplatin-caused
nephrotoxicity remains to be further clarified.
Conclusions
In conclusion, we provided evidences in this study that
cisplatin pretreatment can enhance transduction of
AAV in HNSCC cells, up-regulate TRAIL expression
mediated by AAV, and inhibit tumor cell growth in
vitro. The combined administration of cisplatin and
AAV/TRAIL significantly suppressed both tumor forma-
tion and growth of HNSCC xenografts in nude mice,
protected against cisplatin-caused toxic symptoms.
These findings indicate the potential of this combination
of AAV/TRAIL and cisplatin as a novel therapeutic
strategy for HNSCC. It seems likely, however, that gene
transfer will find its way into the multidisciplinary care
of the head and neck cancer patients, where novel treat-
ments are combined with conventional therapies to
maximize tumor response.
Additional material
Additional file 1: Effect of combining rsTRAIL with cisplatin in vitro.
KB cells were treated with either rsTRAIL (400 ng/mL) or cisplatin (100-
1000 ng/mL) or combination treatment for 24 h. Apoptosis was
determined by MTT assay. Values are mean of three independent
experiments with error bar representing standard deviation of the mean.
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